GeneDx (NASDAQ:WGS) Director Casdin Capital, Llc Acquires 50,000 Shares

08 Jun 2026, 23:42 by Michael Walen · The Markets Daily

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) Director Casdin Capital, Llc purchased 50,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $52.86 per share, for a total transaction of $2,643,000.00. Following the purchase, the director owned 3,707,164 shares in the company, valued at $195,960,689.04. This trade represents a 1.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Casdin Capital, Llc also recently made the following trade(s):

On Thursday, June 4th, Casdin Capital, Llc purchased 150,000 shares of GeneDx stock. The stock was acquired at an average price of $56.44 per share, for a total transaction of $8,466,000.00.
On Wednesday, May 20th, Casdin Capital, Llc purchased 140,000 shares of GeneDx stock. The stock was acquired at an average price of $43.81 per share, for a total transaction of $6,133,400.00.
On Tuesday, May 19th, Casdin Capital, Llc purchased 185,000 shares of GeneDx stock. The stock was acquired at an average price of $42.60 per share, for a total transaction of $7,881,000.00.
On Monday, May 18th, Casdin Capital, Llc purchased 175,000 shares of GeneDx stock. The stock was acquired at an average price of $42.55 per share, for a total transaction of $7,446,250.00.

GeneDx Stock Performance

Shares of WGS stock traded down $0.41 on Monday, hitting $51.80. The company’s stock had a trading volume of 790,359 shares, compared to its average volume of 1,036,153. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The stock’s 50 day moving average is $55.44 and its 200-day moving average is $92.65. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a market capitalization of $1.54 billion, a PE ratio of -19.33 and a beta of 1.96.

GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same quarter last year, the company posted ($0.23) earnings per share. Equities research analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in WGS. Royal Bank of Canada grew its holdings in shares of GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in GeneDx by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after purchasing an additional 453 shares during the last quarter. NewEdge Advisors LLC boosted its position in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after buying an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after buying an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in shares of GeneDx during the second quarter worth $249,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on WGS. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Guggenheim decreased their price target on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Craig Hallum restated a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Canaccord Genuity Group set a $75.00 price target on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $96.43.

Get Our Latest Report on WGS

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

GeneDx Company Profile

(Get Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.